What prompted Kartik to study the entry mechanism of Ebola virus? Read this Science Careers article to find out more about why and how Kartik, Esther Ndungo, a graduate student in his lab, and several other researchers chose to investigate Ebola virus.
VIDEO CAROUSEL
FEATURED NEWS
Featured
LATEST NEWS
Seminar at The Ebola Forum, Rutgers University→
/Kartik spoke at this symposium organized by the working group, "Zoonosis and Society: Interdisciplinary Perspectives of Animal-to-Human Disease" at Rutgers University. Its goal was to integrate the diverse perspectives of sociologists, anthropologists, epidemiologists, ecologists, clinical researchers, and molecular virologists on the Ebola outbreak in West Africa. Watch the video of Kartik's talk (34 minutes).
Researchers Study Ebola Link to Gene in Rare Disease→
/
The Wall Street Journal interviews Kartik and Chandran Lab collaborator Steven Walkley about the connection between the rare genetic disease Niemann-Pick Type C and Ebola virus. Our research raises the possibility that a mutated NPC1 gene offers protection against Ebola infection, just as carriers of sickle-cell disease are protected against malaria. (subscription only)
More coverage on this story at The Scientist and CBSNews.com.
Don’t fear flying during the Ebola crisis: experts→
/
The New York Daily News interviews Kartik about the evolving Ebola epidemic and the risk of airline travel in light of news that someone who later tested positive for the virus traveled by air while infected.
Experimental Drug Would Help Fight Ebola if Supply Increases, Study Finds→
/
The New York Times interviews Kartik about new research that found the experimental Ebola drug ZMapp was successful in treating monkeys infected with the virus.
Ebola Drug’s Success Bolsters Approach for Other Diseases→
/
Bloomberg News speaks with Kartik about ZMapp, the experimental antibody treatment for Ebola, and passive antibody therapeutics for other viral infections.
The Race to Find a Vaccine or Treatment to Stop Ebola→
/
CBSNews.com interviews Kartik about the Ebola outbreak and his research on the virus. Kartik explains how Ebola enters cells, and how understanding this process has been instrumental in identifying new targets for drug development.
An Ebola Vaccine Is Not the Answer→
/
The Atlantic magazine speaks to Kartik about possible strategies to use a vaccine to stop the Ebola outbreak in West Africa, their limitations, and the need for therapeutics.
Kartik appears on Andrea Mitchell Reports→
/
Kartik appears on Andrea Mitchell Reports to discuss Ebola vaccines and treatments and the airlift of Dr. Kent Brantly to the US for treatment.
Ebola Vaccine Possible, but Many Doubts Persist→
/
The New York Times interviews Kartik and Chandran Lab collaborator John Dye (USAMRIID) about the development of new vaccines to protect against Ebola virus, and the challenges inherent in vaccinating a population against a rare and fast-moving virus like Ebola.
Why is there not yet a cure for Ebola?→
/
Kartik speaks to the The New York Daily News about the worsening Ebola epidemic in West Africa, the paucity of available therapeutics, and new approaches to develop them.
Why Are There No Drugs for Ebola Virus?→
/
The Huffington Post features an op-ed co-written by Kartik. He and his co-author (Chandran Lab collaborator) John Dye (USAMRIID) call for innovative academia-industry partnerships and greater investment in research towards meeting this goal.
World War Z: Could a Zombie Virus Happen?→
/
National Geographic interviews Kartik about the scientific possibility that a zombie-inducing virus, of the type featured in the film World War Z, could emerge in real life. [Answer—it's not very likely ;)]
Is a Zombie Apocalypse Possible?→
/
Kartik appears in S5E1 of The Science Channel’s show 'Through The Wormhole with Morgan Freeman' to discuss his research on how Ebola virus infects humans. [And yes, to pontificate about zombifying viruses!].
Einstein Helps Establish $28 Million Consortium To Find Ebola Treatment→
/
The National Institutes of Health (NIH) has awarded a five-year, $28 million grant for a new center for excellence, the 'Viral Hemorrhagic Fever Immunotherapeutic Consortium', that will discover antibody “cocktails” against filoviruses and arenaviruses. The project involves researchers from 15 institutions, including Kartik and a close collaborator at Einstein, Jonathan Lai. Read the press release.
Kartik Chandran, 'Chemistry Kid'→
/
The Scientist features Kartik as a 'Scientist to Watch' for his research on Ebola virus infection mechanisms. The article charts Kartik's career—from his high school chemistry club’s explosive experiments to his innovative work on the surface proteins of viruses.
The Race to Cure Ebola→
/
Could the deadly Ebola virus establish a foothold in the U.S.? Newsweek.com talks to Kartik about this possibility.
Key Protein May Give Ebola Virus Its Opening→
/
The New York Times features our research in Nature that identifies NPC1 as a key protein the deadly Ebola virus needs to infect cells, and a potential target for development of anti-Ebola treatments.
Scientists find weakness in deadly Ebola virus→
/
Reuters features our Nature study describing Niemann-Pick C1 (NPC1) as a critical host factor for cell entry and infection by Ebola virus and Marburg virus.
Researchers Find "Key" Used by Ebola Virus to Unlock Cells and Spread Deadly Infection →
/
Kartik and his collaborators, Thijn Brummelkamp (Netherlands Cancer Institute), John Dye (USAMRIID), and Sean Whelan (Harvard Medical School) have identified a cellular protein, NPC1, that is critical for infection by Ebola virus. This work was published in the August 24 online edition of Nature. See accompaning presser and watch the video.